Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR

被引:61
|
作者
Rahman, Mahboob [1 ]
Ford, Charles E. [1 ]
Cutler, Jeffrey A. [1 ]
Davis, Barry R. [1 ]
Piller, Linda B. [1 ]
Whelton, Paul K. [1 ]
Wright, Jackson T., Jr. [1 ]
Barzilay, Joshua I. [1 ]
Brown, Clinton D. [1 ]
Colon, Pedro J., Sr. [1 ]
Fine, Lawrence J. [1 ]
Grimm, Richard H., Jr. [1 ]
Gupta, Alok K. [1 ]
Baimbridge, Charles [1 ]
Haywood, L. Julian [1 ]
Henriquez, Mario A. [1 ]
Ilamaythi, Ekambaram [1 ]
Oparil, Suzanne [1 ]
Preston, Richard [1 ]
机构
[1] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77030 USA
关键词
CHRONIC KIDNEY-DISEASE; BLOOD-PRESSURE CONTROL; HYPERTENSIVE PATIENTS; PROGRESSION; ASSOCIATION; AMERICAN; DESIGN;
D O I
10.2215/CJN.07800811
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives CKD is common among older patients. This article assesses long-term renal and cardiovascular outcomes in older high-risk hypertensive patients, stratified by baseline estimated GFR (eGFR), and long-term outcome efficacy of 5-year first-step treatment with amlodipine or lisinopril, each compared with chlorthalidone. Design, setting, participants, & measurements This was a long-term post-trial follow-up of hypertensive participants (n=31,350), aged >= 55 years, randomized to receive chlorthalidone, amlodipine, or lisinopril for 4-8 years at 593 centers. Participants were stratified by baseline eGFR (ml/min per 1.73 m(2)) as follows: normal/increased (>= 90; n=8027), mild reduction (60-89; n=17,778), and moderate/severe reduction (<60; n=5545). Outcomes were cardiovascular mortality (primary outcome), total mortality, coronary heart disease, cardiovascular disease, stroke, heart failure, and ESRD. Results After an average 8.8-year follow-up, total mortality was significantly higher in participants with moderate/severe eGFR reduction compared with those with normal and mildly reduced eGFR (P<0.001). in participants with an eGFR <60, there was no significant difference in cardiovascular mortality between chlorthalidone and amlodipine (P=0.64), or chlorthalidone and lisinopril (P=0.56). Likewise, no significant differences were observed for total mortality, coronary heart disease, cardiovascular disease, stroke, or ESRD. Conclusions CKD is associated with significantly higher long-term risk of cardiovascular events and mortality in older hypertensive patients. By eGFR stratum, 5-year treatment with amlodipine or lisinopril was not superior to chlorthalidone in preventing cardiovascular events, mortality, or ESRD during 9-year follow-up. Because data on proteinuria were not available, these findings may not be extrapolated to proteinuric CKD. Clin J Am Soc Nephrol 7: 989-1002, 2012. doi: 10.2215/CJN.07800811
引用
收藏
页码:989 / 1002
页数:14
相关论文
共 50 条
  • [1] Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Barzilay, JI
    Jones, CL
    Davis, BR
    Basile, JN
    Goff, DC
    Ciocon, JO
    Sweeney, ME
    Randall, OS
    DIABETES CARE, 2001, 24 (04) : 654 - 658
  • [2] Clinical outcomes in participants with cardiovascular dysmetabolic syndrome in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Black, H
    Davis, B
    JOURNAL OF HYPERTENSION, 2005, 23 : S146 - S146
  • [3] Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Piller, Linda B.
    Baraniuk, Sarah
    Simpson, Lara M.
    Cushman, William C.
    Massie, Barry M.
    Einhorn, Paula T.
    Oparil, Suzanne
    Ford, Charles E.
    Graumlich, James F.
    Dart, Richard A.
    Parish, David C.
    Retta, Tamrat M.
    Cuyjet, Aloysius B.
    Jafri, Syed Z.
    Furberg, Curt D.
    Saklayen, Mohammad G.
    Thadani, Udho
    Probstfield, Jeffrey L.
    Davis, Barry R.
    CIRCULATION, 2011, 124 (17) : 1811 - U88
  • [4] Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Grimm, RH
    Margolis, KL
    Papademetriou, V
    Cushman, WC
    Ford, CE
    Bettencourt, J
    Alderman, MH
    Basile, JN
    Black, HR
    DeQuattro, V
    Eckfeldt, J
    Hawkins, CM
    Perry, HM
    Proschan, M
    HYPERTENSION, 2001, 37 (01) : 19 - 27
  • [5] Angioedema in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Piller, L
    Ford, C
    Davis, B
    Nwachuku, C
    Black, H
    Oparil, S
    Gappy, S
    Retta, T
    Probstfield, J
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 92A - 92A
  • [6] Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) - Practical implications
    Oparil, S
    HYPERTENSION, 2003, 41 (05) : 1006 - 1009
  • [7] Antihypertensive and lipid-lowering treatment to prevent heart attack (ALLHAT) trial: Interim results
    Davis, B
    Furberg, CD
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (01) : 325 - 325
  • [8] Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Pressel, S
    Davis, BR
    Louis, GT
    Whelton, P
    Adrogue, H
    Egan, D
    Farber, M
    Payne, G
    Probstfield, J
    Ward, H
    CONTROLLED CLINICAL TRIALS, 2001, 22 (06): : 674 - 686
  • [9] Clinical outcomes in participants with cardiovascular dysmetabolic syndrome in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
    Davis, BR
    Black, HR
    CIRCULATION, 2004, 110 (17) : 796 - 796
  • [10] Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
    Dhruva, Sanket S.
    Huang, Chenxi
    Spatz, Erica S.
    Coppi, Andreas C.
    Warner, Frederick
    Li, Shu-Xia
    Lin, Haiqun
    Xu, Xiao
    Furberg, Curt D.
    Davis, Barry R.
    Pressel, Sara L.
    Coifman, Ronald R.
    Krumholz, Harlan M.
    HYPERTENSION, 2017, 70 (01) : 94 - 102